Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

MBX Biosciences Q3 2026 Results: Net Loss of $62.4M, Loss Widens

MBX Biosciences reported a significant increase in operating expenses for the nine months ended September 30, 2026, with research and development costs rising to $81.5 million. The company's cash and marketable securities position strengthened to approximately $481.6 million following public offerings, while the accumulated deficit grew to $347.5 million. As of November 5, 2026, the company had 49,656,265 shares of common stock outstanding.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-62.4-21.6
EPS (diluted, $ a share)$-1.29$-0.63

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

MBX Biosciences, Inc.: key numbers

Share price
$53.10Close, Nov 17
Market cap
$2.64B
Shares outstanding
49.66MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from MBX Biosciences, Inc.

All →
7:57 AM ET Form 4
Insider Selling

MBX Biosciences Chairman, President and CEO Steven L. Hoerter Sells $268K of Stock

Steven L. Hoerter, Chairman, President and CEO, sold 4,893 shares of MBX Biosciences, Inc. at $54.82 a share, worth $268K in total on Nov 10, 2026. Shares held after the trade: 78,045 (-5.9%).

Value
$268K
Shares
4,893
Price
$54.82
Role
Chairman, President and CEO
Holding change
-5.9%
Trade date
Nov 10, 2026
4:06 PM ET 8-K
Financial Results

MBX Biosciences Financial Results

MBX Biosciences reported third quarter 2026 financial results, highlighting the initiation of its pivotal Phase 3 oPTimize trial for canvuparatide in hypoparathyroidism. The company ended the quarter with $481.6 million in cash and investments, which is expected to fund operations into 2029.

Term
Q3 2026

“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy.”

Steve Hoerter, Chairman and Chief Executive Officer

“With a strong balance sheet and cash runway into 2029, we believe we are well positioned to advance canvuparatide through pivotal development while continuing to invest in our growing obesity portfolio.”

Steve Hoerter, Chairman and Chief Executive Officer
4:11 PM ET Form 4
Insider Selling

MBX Biosciences CMO Salomon Azoulay Sells $20.1K of Stock

Salomon Azoulay, CMO, sold 373 shares of MBX Biosciences, Inc. at $53.96 a share, worth $20.1K in total on Nov 4, 2026. Shares held after the trade: 14,026 (-2.6%).

Value
$20.1K
Shares
373
Price
$53.96
Role
CMO
Holding change
-2.6%
Trade date
Nov 4, 2026
8:11 AM ET 8-K
Executive Compensation

MBX Biosciences Executive Compensation

MBX Biosciences appointed Peter Radovich to its Board of Directors as a Class I director, effective October 20, 2026. In connection with his appointment, Mr. Radovich received an initial grant of non-qualified stock options for 18,200 shares and will receive cash compensation according to the company's non-employee director compensation policy.

Counterparty
Peter Radovich

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.